Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study

Miriam Nickel, Alessandro Simonati, David Jacoby, Susanne Lezius, Dirk Kilian, Benjamin Van de Graaf, Odelya E Pagovich, Barry Kosofsky, Kaleb Yohay, Matthew Downs, Peter Slasor, Temitayo Ajayi, Ronald G Crystal, Alfried Kohlschütter, Dolan Sondhi, Angela Schulz, Miriam Nickel, Alessandro Simonati, David Jacoby, Susanne Lezius, Dirk Kilian, Benjamin Van de Graaf, Odelya E Pagovich, Barry Kosofsky, Kaleb Yohay, Matthew Downs, Peter Slasor, Temitayo Ajayi, Ronald G Crystal, Alfried Kohlschütter, Dolan Sondhi, Angela Schulz

Abstract

Background: Late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, characterised by rapid psychomotor decline and epilepsy, is caused by deficiency of the lysosomal enzyme tripeptidyl peptidase 1. We aimed to analyse the characteristics and rate of progression of CLN2 disease in an international cohort of patients.

Methods: We did an observational cohort study using data from two independent, international datasets of patients with untreated genotypically confirmed CLN2 disease: the DEM-CHILD dataset (n=74) and the Weill Cornell Medical College (WCMC) dataset (n=66). Both datasets included quantitative rating assessments with disease-specific clinical domain scores, and disease course was measured longitudinally in 67 patients in the DEM-CHILD cohort. We analysed these data to determine age of disease onset and diagnosis, as well as disease progression-measured by the rate of decline in motor and language summary scores (on a scale of 0-6 points)-and time from first symptom to death.

Findings: In the combined DEM-CHILD and WCMC dataset, median age was 35·0 months (IQR 24·0-38·5) at first clinical symptom, 37·0 months (IQR 35·0 -42·0) at first seizure, and 54·0 months (IQR 47·5-60·0) at diagnosis. Of 74 patients in the DEM-CHILD dataset, the most common first symptoms of disease were seizures (52 [70%]), language difficulty (42 [57%]), motor difficulty (30 [41%]), behavioural abnormality (12 [16%]), and dementia (seven [9%]). Among the 41 patients in the DEM-CHILD dataset for whom longitudinal assessments spanning the entire disease course were available, a rapid annual decline of 1·81 score units (95% CI 1·50-2·12) was seen in motor-language summary scores from normal (score of 6) to no function (score of 0), which occurred over approximately 30 months. Among 53 patients in the DEM-CHILD cohort with available data, the median time between onset of first disease symptom and death was 7·8 years (SE 0·9) years.

Interpretation: In view of its natural history, late-infantile CLN2 disease should be considered in young children with delayed language acquisition and new onset of seizures. CLN2 disease has a largely predictable time course with regard to the loss of language and motor function, and these data might serve as historical controls for the assessment of current and future therapies.

Funding: EU Seventh Framework Program, German Ministry of Education and Research, EU Horizon2020 Program, National Institutes of Health, Nathan's Battle Foundation, Cures Within Reach Foundation, Noah's Hope Foundation, Hope4Bridget Foundation.

Copyright © 2018 Elsevier Ltd. All rights reserved.

Figures

Figure 1:. Genotype distribution in different patient…
Figure 1:. Genotype distribution in different patient cohorts
Common mutations are c.622C→T and c.509–1G→C.
Figure 2:. Age at first clinical sign,…
Figure 2:. Age at first clinical sign, first seizure, and diagnosis
Data are combined from both DEM-CHILD and WCMC cohorts (n=140). Boxes show median values (middle lines) with 25th and 75th percentiles; whiskers show values within two-thirds of the IQR. Circles represent data points that fall outside this range. CLN2= Late-infantile neuronal ceroid lipofuscinosis type 2.
Figure 3:. Kaplan-Meier analysis of survival from…
Figure 3:. Kaplan-Meier analysis of survival from onset of first symptom in the DEM-CHILD cohort
Data for age at first symptom onset was available for 53 patients in the DEM-CHILD cohort.
Figure 4:. Longitudinal motor–language scores for the…
Figure 4:. Longitudinal motor–language scores for the DEM-CHILD core cohort
Data are cross-sectional summaries of disease severity for all patients in the DEM-CHILD core data cohort for whom longitudinal scoring data were available (n=41).
Figure 5:. Motor–language scores of comparison cohorts…
Figure 5:. Motor–language scores of comparison cohorts superimposed on DEM-CHILD core data
Motor-language score data for DEM-CHILD comparison cohort 1 (A), WCMC comparison cohort 1 (B), DEM-CHILD comparison cohort 2 (C), and WCMC comparison cohort 2 (D). Each assessment is shown as single blue point. Longitudinal assessments for each patient are linked by dashed red lines. Mean scores and 95% CIs, and 10th, 25th, 75th, and 90th percentiles for the DEM-CHILD core data are shown for comparison.

Source: PubMed

3
Abonnieren